

ABSTRAK

PERBANDINGAN EFEKTIVITAS SACUBITRIL/VALSARTAN DENGAN ENALAPRIL PADA PASIEN GAGAL JANTUNG: *LITERATURE REVIEW*

*Jitayu Sekarininta Mumpun*¹, *Laksmi Maharani*², *Nialiana Endah Endriastuti*²

Latar Belakang: ARNI adalah terapi baru untuk pasien gagal jantung yang telah diakui pada 2016, yang merupakan kombinasi antara sacubitril (Neprilisin Inhibitor) dengan valsartan (angiotensin receptor blocker). Penelitian ini bertujuan untuk mengetahui perbandingan efektivitas penggunaan sacubitril/valsartan dengan enalapril pada pasien gagal jantung.

Metodologi: Penelitian ini dilakukan dengan metode *literature review*. Pencarian artikel menggunakan kata kunci PICO pada *database* Cochrane Library dan PubMed. Kata kunci yang digunakan yaitu *heart failure*, sacubitril/valsartan atau LCZ696, enalapril, dan *efficacy or effectiveness*. Kriteria inklusi pada penelitian yaitu artikel dalam bahasa inggris, tersedia *full text* dan bebas akses, tahun publikasi 2010-2020, dan penelitian RCT. Kriteria eksklusi yaitu artikel *review*.

Hasil Penelitian: Pencarian dilakukan 10 Juli hingga 23 Juli 2020 dan 20 Desember 2020. Didapatkan hasil pencarian 160 artikel, setelah dilakukan seleksi dan eligibilitas diperoleh 16 artikel sesuai dengan kriteria inklusi sebagai artikel primer, dan 2 artikel ditambahkan sebagai artikel sekunder. Penelitian membuktikan bahwa sacubitril/valsartan menurunkan kejadian readmisi dan memiliki skor kualitas hidup yang lebih baik dibandingkan enalapril, serta menurunkan resiko kematian pada populasi pasien berdasarkan resiko perkembangan klinis pasien, penyebab kematian, *background* terapi, dan pasien dengan skor MAGGIC dan EMPHASIS-HF.

Kesimpulan: Berdasarkan penelitian primer PARADIGM-HF dan 15 artikel analisis lanjutan, diketahui bahwa penggunaan sacubitril/valsartan lebih bermanfaat dalam menurunkan resiko kematian dan rawat inap kembali, serta meningkatkan kualitas hidup dibandingkan enalapril pada pasien gagal jantung.

Kata kunci: sacubitril/valsartan, enalapril, gagal jantung, *literature review*

¹Mahasiswa Jurusan Farmasi FIKes Universitas Jenderal Soedirman

²Departemen Farmasi FIKes Universitas Jenderal Soedirman

ABSTRACT

COMPARISON OF THE EFFECTIVENESS OF SACUBITRIL/VALSARTAN WITH ENALAPRIL IN HEART FAILURE PATIENTS: LITERATURE REVIEW

Jitayu Sekarininta Mumpun¹, Laksmi Maharani², Nialiana Endah Endriastuti²

Background: ARNI is a new therapy for heart failure patients that have been approved since 2016, which is a combination of sacubitril (Neprilisin Inhibitor) and valsartan (angiotensin receptor blocker). The aim of this study was to compare the effectiveness of sacubitril/valsartan and enalapril in heart failure patients.

Methods: This research was conducted using a literature review method. Database used were Cochrane Library and PubMed. Keywords used for article searching was based on PICO which were heart failure, sacubitril/valsartan or LCZ696, enalapril, and efficacy or effectiveness. The inclusion criteria in this study were articles in English, available in full text and free access, published in 2010-2020, and RCT research. The exclusion criteria was review articles.

Results: The searching was conducted from 10 July to 23 July 2020 and 20 December 2020. From this searching, researcher obtained 160 articles, after the process of selection and eligibility, 16 articles were included according to the inclusion criteria as primary articles, and 2 articles were included as secondary articles. Studies have shown that sacubitril/valsartan reduces the incidence of readmission and has a better quality of life score than enalapril, and also decreases the risk of death in the patient population based on the patient's clinical development risk, cause of death, therapeutic background, and patients with MAGGIC and EMPHASIS-HF scores.

Conclusion: According to primary research of PARADIGM-HF and 15 advanced analysis article, it's known that the usage of sacubitril/valsartan is more beneficial in decreases the risk of death and reduces the incidence of readmission, and also has a better quality of life score than enalapril in heart failure patients.

Keywords : sacubitril/valsartan, enalapril, heart failure, literature review

¹Pharmacy Student, Faculty of Health Sciences, Jenderal Soedirman University

²Department of Pharmacy, Faculty of Health Sciences, Jenderal Soedirman University